TUMOR MARKERS EXPRESSION LEVELS IN GASTRIC CANCER PATIENT'S PERIPHERAL BLOOD BY RT-PCR ASSESSMENT.
Journal
Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery
ISSN: 2317-6326
Titre abrégé: Arq Bras Cir Dig
Pays: Brazil
ID NLM: 9100283
Informations de publication
Date de publication:
2024
2024
Historique:
received:
25
09
2023
accepted:
10
10
2023
medline:
9
2
2024
pubmed:
7
2
2024
entrez:
7
2
2024
Statut:
epublish
Résumé
Hematological recurrence is the second most frequent cause of failure in the treatment of gastric cancer. The detection of circulating tumor markers in peripheral blood by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) method may be a useful tool to predict recurrence and determine the patient's prognosis. However, no consensus has been reached regarding the association between the tumor markers level in peripheral blood and its impact on patient survival. To evaluate the expression of the circulating tumor markers CK20 and MUC1 in peripheral blood samples from patients with gastric cancer by qRT-PCR, and to verify the association of their expression levels with clinicopathological characteristics and survival. A total of 31 patients with gastric adenocarcinoma were prospectively included in this study. CK20 and MUC1 expression levels were analyzed from peripheral blood by the qRT-PCR technique. There was no statistically significant (p>0.05) association between CK20 expression levels and clinical, pathological, and surgical features. Higher MUC1 expression levels were associated with female patients (p=0.01). There was a correlation between both gene levels (R=0.81, p<0.001), and CK20 level and tumor size (R=0.39, p=0.034). CK20 and MUC1 expression levels could be assessed by qRT-PCR from total peripheral blood samples of patients with gastric cancer. CK20 levels were correlated to MUC1 levels as well as to tumor size. There was no difference in disease-free survival and overall survival regarding both genetic markers expression in this series.
Sections du résumé
BACKGROUND
BACKGROUND
Hematological recurrence is the second most frequent cause of failure in the treatment of gastric cancer. The detection of circulating tumor markers in peripheral blood by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) method may be a useful tool to predict recurrence and determine the patient's prognosis. However, no consensus has been reached regarding the association between the tumor markers level in peripheral blood and its impact on patient survival.
AIMS
OBJECTIVE
To evaluate the expression of the circulating tumor markers CK20 and MUC1 in peripheral blood samples from patients with gastric cancer by qRT-PCR, and to verify the association of their expression levels with clinicopathological characteristics and survival.
METHODS
METHODS
A total of 31 patients with gastric adenocarcinoma were prospectively included in this study. CK20 and MUC1 expression levels were analyzed from peripheral blood by the qRT-PCR technique.
RESULTS
RESULTS
There was no statistically significant (p>0.05) association between CK20 expression levels and clinical, pathological, and surgical features. Higher MUC1 expression levels were associated with female patients (p=0.01). There was a correlation between both gene levels (R=0.81, p<0.001), and CK20 level and tumor size (R=0.39, p=0.034).
CONCLUSIONS
CONCLUSIONS
CK20 and MUC1 expression levels could be assessed by qRT-PCR from total peripheral blood samples of patients with gastric cancer. CK20 levels were correlated to MUC1 levels as well as to tumor size. There was no difference in disease-free survival and overall survival regarding both genetic markers expression in this series.
Identifiants
pubmed: 38324850
pii: S0102-67202023000100351
doi: 10.1590/0102-672020230071e1789
pmc: PMC10841496
pii:
doi:
Substances chimiques
Keratin-20
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1789Références
Cancer. 2002 Jun 1;94(11):2867-73
pubmed: 12115374
Int J Cancer. 2003 May 20;105(1):136-43
pubmed: 12672044
Ann Surg Oncol. 2013 Feb;20(2):515-21
pubmed: 22546997
Clin Biochem. 2011 Mar;44(4):325-30
pubmed: 21130081
Cancer. 2013 Nov 15;119(22):3984-91
pubmed: 23963829
Arq Bras Cir Dig. 2023 Sep 15;36:e1752
pubmed: 37729281
Lancet. 1991 Nov 16;338(8777):1227-9
pubmed: 1719320
Oncology. 2015;89(5):294-303
pubmed: 26315108
Int J Cancer. 2015 Jan 1;136(1):21-33
pubmed: 24803400
J Clin Oncol. 1998 Jan;16(1):128-32
pubmed: 9440733
Int J Clin Oncol. 2013 Oct;18(5):752-61
pubmed: 23775112
Arq Bras Cir Dig. 2022 Jun 17;35:e1648
pubmed: 35730877
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Arq Bras Cir Dig. 2021 May 14;34(1):e1563
pubmed: 34008707
Cancer. 2001 Oct 15;92(8):2056-64
pubmed: 11596020
Cancer Res. 1997 Aug 1;57(15):3106-10
pubmed: 9242433
J Natl Cancer Inst. 1999 Jul 7;91(13):1113-24
pubmed: 10393719
Int J Mol Sci. 2014 May 07;15(5):7958-73
pubmed: 24810688
Eur J Cancer. 2000 Aug;36(13 Spec No):1681-94
pubmed: 10959054
Int J Cancer. 1998 Apr 17;79(2):133-8
pubmed: 9583726
Clin Chim Acta. 2006 May;367(1-2):55-61
pubmed: 16403482
Jpn J Clin Oncol. 2000 Nov;30(11):499-503
pubmed: 11155920
Oncol Rep. 2006 Aug;16(2):411-6
pubmed: 16820924
Scand J Gastroenterol. 2005 Jul;40(7):843-9
pubmed: 16109661
Pathobiology. 2012;79(3):154-61
pubmed: 22286119
Int J Mol Med. 2003 Feb;11(2):217-21
pubmed: 12525881
Virchows Arch. 2002 Mar;440(3):304-10
pubmed: 11889602
Surgery. 1996 Apr;119(4):397-402
pubmed: 8644003
Cancer. 1997 Oct 15;80(8):1393-8
pubmed: 9338462
Int J Cancer. 1998 Aug 21;79(4):402-10
pubmed: 9699534
Anticancer Res. 2007 Mar-Apr;27(2):1207-12
pubmed: 17465264
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
Arq Bras Cir Dig. 2017 Jan-Mar;30(1):30-34
pubmed: 28489165
Br J Cancer. 2006 Jul 17;95(2):218-25
pubmed: 16755296
World J Gastroenterol. 2007 Aug 14;13(30):4122-5
pubmed: 17696234
Cancer Lett. 2002 Sep 26;183(2):195-203
pubmed: 12065095